This figure' shows that the decay "chain" starts with an a decay of 2Ac to produce "Fr, which itself undergoes a decay to "X1", and so on, until the final production of the stable "Bi isotope via a beta- decay process from "XS". Note that isotope "X2" has two different decay channels, both of which result in "XS": 98% of "X2" undergoes B decay to "X3" (which subsequently decays by emitting a to produce XS"), while 2% of X2" decays to "X4" via a decay (which subsequently undergoes B* decay to "X5"). 1. Given the type of decay process, provide the element and nucleon number (e.g. 2"Fr) for each of the isotopes X1, X2, X3, X4 and XS. 2. Assume a chemist in Dr. Ramogida's lab requires 8 hours from the time of receipt of 2Ac to incorporate it into a chemically synthesized carrier compound that can be used for cancer treatment. If they are given 0.450 mg of 2Ac, what is the mass of *Ac remaining at the end of the 8 hours, given its half-life of 9.9 days? 3. If their compound is shipped around the world for treatment of cancer patients, a key consideration is how long it remains active. Starting with the amount that leaves Dr. Ramogida's lab, for how long does at least 10% of the *Ac remain, which could be used for treatment? 4. The half-life of 21Fr is considerably shorter than "Ac: 4.8 minutes. Would you recommend to Dr. Ramogida's team to try to synthesize molecules that can target Francium to tumours, rather than using Actinium? Explain your reasoning. Figure adapted from "Development of Ac Radiopharmaceuticals: TRIUMF Perspectives and Experiences", by Robertson, Ramogida, Schaffer and Radchenko. Current Radiopharmaceuticals 11, 156 (2018)

Chemistry: An Atoms First Approach
2nd Edition
ISBN:9781305079243
Author:Steven S. Zumdahl, Susan A. Zumdahl
Publisher:Steven S. Zumdahl, Susan A. Zumdahl
Chapter18: The Nucleus: A Chemist's View
Section: Chapter Questions
Problem 28E
icon
Related questions
Question

question 2 please

|225 дс|
9.9 d
a
221Fr
d = days
h = hours
4.8 m
m = minutes
s = seconds
a
ms = milliseconds
us = microseconds
X1
32 ms
a
X2
X3
98% B"
45.6 m
4.2 us
2% a
|209Bİ
B-
X4
X5
2.2 m
3.3 h
stable
This figure' shows that the decay "chain" starts with an a decay of 225Ac to produce 221Fr, which itself
undergoes a decay to "X1", and so on, until the final production of the stable 20°B¡ isotope via a beta-
decay process from "X5". Note that isotope "X2" has two different decay channels, both of which result
in "X5": 98% of “X2" undergoes B decay to "X3" (which subsequently decays by emitting a to produce
"X5"), while 2% of "X2" decays to "X4" via a decay (which subsequently undergoes B" decay to "X5").
1.
Given the type of decay process, provide the element and nucleon number (e.g. 22"Fr) for each of
the isotopes X1, X2, X3, X4 and X5.
Assume a chemist in Dr. Ramogida's lab requires 8 hours from the time of receipt of
225
2.
Ac to
incorporate it into a chemically synthesized carrier compound that can be used for cancer
treatment. If they are given 0.450 mg of 225 Ac, what is the mass of 225
Ac remaining at the end of the
8 hours, given its half-life of 9.9 days?
3.
If their compound is shipped around the world for treatment of cancer patients, a key
consideration is how long it remains active. Starting with the amount that leaves Dr. Ramogida's
lab, for how long does at least 10% of the 225Ac remain, which could be used for treatment?
The half-life of 221Fr is considerably shorter than 225AC: 4.8 minutes. Would you recommend to Dr.
Ramogida's team to try to synthesize molecules that can target Francium to tumours, rather than
using Actinium? Explain your reasoning.
4.
"Figure adapted from "Development of 225AC Radiopharmaceuticals: TRIUMF Perspectives and Experiences", by
Robertson, Ramogida, Schaffer and Radchenko. Current Radiopharmaceuticals 11, 156 (2018)
Transcribed Image Text:|225 дс| 9.9 d a 221Fr d = days h = hours 4.8 m m = minutes s = seconds a ms = milliseconds us = microseconds X1 32 ms a X2 X3 98% B" 45.6 m 4.2 us 2% a |209Bİ B- X4 X5 2.2 m 3.3 h stable This figure' shows that the decay "chain" starts with an a decay of 225Ac to produce 221Fr, which itself undergoes a decay to "X1", and so on, until the final production of the stable 20°B¡ isotope via a beta- decay process from "X5". Note that isotope "X2" has two different decay channels, both of which result in "X5": 98% of “X2" undergoes B decay to "X3" (which subsequently decays by emitting a to produce "X5"), while 2% of "X2" decays to "X4" via a decay (which subsequently undergoes B" decay to "X5"). 1. Given the type of decay process, provide the element and nucleon number (e.g. 22"Fr) for each of the isotopes X1, X2, X3, X4 and X5. Assume a chemist in Dr. Ramogida's lab requires 8 hours from the time of receipt of 225 2. Ac to incorporate it into a chemically synthesized carrier compound that can be used for cancer treatment. If they are given 0.450 mg of 225 Ac, what is the mass of 225 Ac remaining at the end of the 8 hours, given its half-life of 9.9 days? 3. If their compound is shipped around the world for treatment of cancer patients, a key consideration is how long it remains active. Starting with the amount that leaves Dr. Ramogida's lab, for how long does at least 10% of the 225Ac remain, which could be used for treatment? The half-life of 221Fr is considerably shorter than 225AC: 4.8 minutes. Would you recommend to Dr. Ramogida's team to try to synthesize molecules that can target Francium to tumours, rather than using Actinium? Explain your reasoning. 4. "Figure adapted from "Development of 225AC Radiopharmaceuticals: TRIUMF Perspectives and Experiences", by Robertson, Ramogida, Schaffer and Radchenko. Current Radiopharmaceuticals 11, 156 (2018)
Expert Solution
steps

Step by step

Solved in 3 steps

Blurred answer
Knowledge Booster
Nuclear Reactions
Learn more about
Need a deep-dive on the concept behind this application? Look no further. Learn more about this topic, chemistry and related others by exploring similar questions and additional content below.
Recommended textbooks for you
Chemistry: An Atoms First Approach
Chemistry: An Atoms First Approach
Chemistry
ISBN:
9781305079243
Author:
Steven S. Zumdahl, Susan A. Zumdahl
Publisher:
Cengage Learning
Chemistry
Chemistry
Chemistry
ISBN:
9781133611097
Author:
Steven S. Zumdahl
Publisher:
Cengage Learning
Chemistry
Chemistry
Chemistry
ISBN:
9781305957404
Author:
Steven S. Zumdahl, Susan A. Zumdahl, Donald J. DeCoste
Publisher:
Cengage Learning
Introductory Chemistry: A Foundation
Introductory Chemistry: A Foundation
Chemistry
ISBN:
9781337399425
Author:
Steven S. Zumdahl, Donald J. DeCoste
Publisher:
Cengage Learning
Principles of Instrumental Analysis
Principles of Instrumental Analysis
Chemistry
ISBN:
9781305577213
Author:
Douglas A. Skoog, F. James Holler, Stanley R. Crouch
Publisher:
Cengage Learning
Chemistry by OpenStax (2015-05-04)
Chemistry by OpenStax (2015-05-04)
Chemistry
ISBN:
9781938168390
Author:
Klaus Theopold, Richard H Langley, Paul Flowers, William R. Robinson, Mark Blaser
Publisher:
OpenStax